Obsidian Therapeutics Announces Bristol Myers Squibb Opt-In of cytoDRiVE™ Cell Therapy Candidate
Bristol Myers Squibb (NYSE:BMY) has exercised its option for an exclusive worldwide license to a cell therapy candidate utilizing Obsidian Therapeutics' cytoDRiVE™ technology, which aims to control the expression of CD40L, an immunomodulatory factor. This marks the first opt-in decision from Bristol Myers since their collaboration began in January 2019. Obsidian stands to receive potential milestone and royalty payments as part of this agreement, signaling validation of its innovative platform and the advancement of its pipeline programs in cancer therapies.
- Bristol Myers Squibb opted for an exclusive license of Obsidian's cell therapy candidate.
- Potential milestone and royalty payments for Obsidian from this agreement.
- Validation of Obsidian's cytoDRiVE™ technology.
- Advancement of Obsidian's controllable tumor infiltrating lymphocyte (TIL) therapy pipeline.
- None.
CAMBRIDGE, Mass., Sept. 15, 2020 /PRNewswire/ -- Obsidian Therapeutics, Inc., a biotechnology company pioneering controllable cell and gene therapies, today announced that Bristol Myers Squibb (NYSE:BMY) has exercised its option to an exclusive worldwide license to a cell therapy candidate based on Obsidian's cytoDRiVE™ technology for the controlled expression of the immunomodulatory factor CD40L. This announcement marks the first opt-in decision by Bristol Myers Squibb since the companies announced their collaboration to develop novel cell therapies in January 2019. Under the terms of the agreement, Obsidian is eligible to receive potential future milestone and royalty payments.
"We are very interested in exploring innovative approaches to developing engineered cell therapies, including the cytoDRiVE™ platform," said Rupert Vessey, D. Phil., Executive Vice President, Research and Early Development, Bristol Myers Squibb. "By controlling the expression of armed payloads like CD40L, Obsidian's cell therapy candidates may have the potential to overcome tumor microenvironment resistance and unlock the power of cell therapy in solid tumors and other malignancies."
"This announcement marks an important milestone validating Obsidian's cytoDRiVE™ platform, and we look forward to continuing to work with Bristol Myers Squibb to bring powerful new immunotherapies to patients," said Paul K. Wotton, Ph.D., Chief Executive Officer of Obsidian Therapeutics. "We are also pleased with the pace with which our own pipeline programs are progressing as we continue to advance our lead controllable tumor infiltrating lymphocyte (TIL) therapy to the clinic."
About Obsidian Therapeutics
Obsidian Therapeutics is a biotechnology company pioneering controllable cell and gene therapies to deliver transformative outcomes for patients with intractable diseases. Obsidian's proprietary cytoDRiVE™ technology provides a way to control protein degradation using FDA-approved small molecules, permitting precise control of the timing and level of protein expression. The cytoDRiVE™ platform can be applied to design controllable intracellular, membrane and secreted proteins for cell and gene therapies as well as other applications. The Company's initial applications focus on developing novel cell therapies for the treatment of cancer. Obsidian is headquartered in Cambridge, Mass. For more information, please visit www.obsidiantx.com.
Media Contact:
Maggie Beller
Russo Partners, LLC
Maggie.beller@russopartnersllc.com
646-942-5631
View original content to download multimedia:http://www.prnewswire.com/news-releases/obsidian-therapeutics-announces-bristol-myers-squibb-opt-in-of-cytodrive-cell-therapy-candidate-301130868.html
SOURCE Obsidian Therapeutics
FAQ
What is the significance of Bristol Myers Squibb opting in for Obsidian's cell therapy candidate?
When did Bristol Myers Squibb begin its collaboration with Obsidian Therapeutics?
What technology does Obsidian Therapeutics use for its cell therapy candidate?
What potential benefits does Obsidian's technology offer in cancer therapies?
